Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use

Cheng-Kuang Yang; Tai-Lung Cha; Yen-Hwa Chang; Shu-Pin Huang; Jen-Tai Lin; Shian-Shiang Wang; Chao-Yuan Huang; See-Tong Pang

Journal of the Formosan Medical Association (Apr 2023)

Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use

Cheng-Kuang Yang,
Tai-Lung Cha,
Yen-Hwa Chang,
Shu-Pin Huang,
Jen-Tai Lin,
Shian-Shiang Wang,
Chao-Yuan Huang,
See-Tong Pang

Affiliations

Cheng-Kuang Yang: Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taiwan
Tai-Lung Cha: Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taiwan
Yen-Hwa Chang: Division of General Urology, Department of Urology, Taipei Veterans General Hospital, Taiwan; Department of Urology, National Yang-Ming University School of Medicine, Taiwan
Shu-Pin Huang: Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan
Jen-Tai Lin: Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Taiwan
Shian-Shiang Wang: Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taiwan; Institute of Medicine, Chung Shan Medical University, Taiwan; Department of Applied Chemistry, National Chi Nan University, Taiwan
Chao-Yuan Huang: Department of Urology, National Taiwan University Hospital, Taiwan; College of Medicine, National Taiwan University, Taiwan; Corresponding author. Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taiwan, No.7, Chung Shan S. Rd.(Zhongshan S. Rd.), Zhongzheng Dist., Taipei City 100225, Taiwan.
See-Tong Pang: Graduate Institute of Clinical Medical Science, College of Medicine, Chang Gung University, Taiwan; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taiwan; Corresponding author. Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taiwan, No. 5 Fuxing Street, Guishan District, Taoyuan 333, Taiwan.

Journal volume & issue: Vol. 122, no. 4
pp. 299 – 308

Abstract

Read online

Darolutamide, a second-generation androgen receptor inhibitor (SGARI), has been shown to increase metastasis-free survival and overall survival among men with non-metastatic castration-resistant prostate cancer (nmCRPC). Its unique chemical structure potentially provides efficacy and safety advantages over the SGARIs apalutamide and enzalutamide, which are also indicated for nmCRPC. Despite a lack of direct comparisons, the SGARIs appear to have similar efficacy, safety, and quality of life (QoL) results. Indirect evidence suggests that darolutamide is preferred for its good adverse event profile, an attribute valued by physicians, patients, and their caregivers for maintaining QoL. Darolutamide and others in its class are costly; access may be a challenge for many patients and may lead to modifications to guideline-recommended regimens.

Published in Journal of the Formosan Medical Association

ISSN: 0929-6646 (Print)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General)
Website: http://www.journals.elsevier.com/journal-of-the-formosan-medical-association/

About the journal

Abstract

Keywords